PL3368046T3 - Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania - Google Patents

Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania

Info

Publication number
PL3368046T3
PL3368046T3 PL16859111.3T PL16859111T PL3368046T3 PL 3368046 T3 PL3368046 T3 PL 3368046T3 PL 16859111 T PL16859111 T PL 16859111T PL 3368046 T3 PL3368046 T3 PL 3368046T3
Authority
PL
Poland
Prior art keywords
behaviour
brain function
synthetic composition
modulating brain
modulating
Prior art date
Application number
PL16859111.3T
Other languages
English (en)
Inventor
Bruce Mcconnell
Emma ELISON
Louise Kristine VIGSNÆS
Original Assignee
Glycom A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycom A/S filed Critical Glycom A/S
Publication of PL3368046T3 publication Critical patent/PL3368046T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL16859111.3T 2015-10-28 2016-10-28 Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania PL3368046T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201570696 2015-10-28
DKPA201670100 2016-02-24
PCT/DK2016/050344 WO2017071715A1 (en) 2015-10-28 2016-10-28 Synthetic composition and method for modulating brain function and behaviour

Publications (1)

Publication Number Publication Date
PL3368046T3 true PL3368046T3 (pl) 2022-11-28

Family

ID=58629784

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16859111.3T PL3368046T3 (pl) 2015-10-28 2016-10-28 Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania

Country Status (7)

Country Link
US (2) US10835545B2 (pl)
EP (1) EP3368046B1 (pl)
CN (1) CN108348535B (pl)
DK (1) DK3368046T3 (pl)
ES (1) ES2927009T3 (pl)
PL (1) PL3368046T3 (pl)
WO (1) WO2017071715A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017190755A1 (en) * 2016-05-05 2017-11-09 Glycom A/S Composition comprising hmos for use in the treatment of mast cell mediated visceral hypersensitivity and/or pain
US11224605B2 (en) 2016-05-19 2022-01-18 Glycom A/S Synthetic composition
WO2018207110A1 (en) * 2017-05-09 2018-11-15 Glycom A/S Synthetic composition for microbiota modulation
EP3630123A4 (en) * 2017-05-24 2020-10-28 Glycom A/S SYNTHETIC COMPOSITION CONSISTING OF ONE OR MORE HUMAN MILK OLIGOSACCHARIDES (HMOS)
WO2019087140A1 (en) * 2017-11-02 2019-05-09 Glycom A/S One or more hmos for reducing or preventing fatigue and/or improving focus or concentration
KR20190130720A (ko) * 2018-05-15 2019-11-25 (주)에이피테크놀로지 2'-푸코실락토오스를 포함하는 뇌졸중 예방용 조성물
PT3897902T (pt) * 2018-12-19 2023-12-06 Glycom As Separação de oligossacáridos
CN114761023A (zh) * 2019-11-27 2022-07-15 格礼卡姆股份公司 Hmo混合物
CN114786501A (zh) * 2019-12-11 2022-07-22 雀巢产品有限公司 用于减少婴儿和幼儿的伤害感觉和/或其他健康益处的组合物
JP7542065B2 (ja) * 2019-12-19 2024-08-29 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 上昇した４－エチルフェニル硫酸と関連付けられた状態の治療およびリスクを低減する組成物および方法
WO2022118269A1 (en) * 2020-12-04 2022-06-09 Glycom A/S Human milk oligosaccharides for use in supporting maturation or improvement of sleeping patterns
US20260165955A1 (en) * 2022-03-18 2026-06-18 Meiji Co., Ltd. Composition for controlling growth of bacteria of the genus collinsella and use thereof
EP4536241A1 (en) 2022-06-09 2025-04-16 Société des Produits Nestlé S.A. Nutritional composition comprising gos and hmos

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2796082B1 (fr) 1999-07-07 2003-06-27 Centre Nat Rech Scient Procede de production d'oligosaccharides
PL1991690T3 (pl) 2006-03-09 2014-07-31 Centre Nat Rech Scient Sposób wytwarzania sialilowanych oligosacharydów
EP2417144B1 (en) 2009-04-07 2017-08-23 Glycom A/S Synthesis of 2'-o-fucosyllactose
JP2012532195A (ja) * 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
EP2289527B1 (en) 2009-08-25 2018-02-21 Nestec S.A. Bifidobacterium longum and functional GI disorders
US8993740B2 (en) 2010-02-19 2015-03-31 Glycom A/S Method for preparation of the tetrasaccharide lacto-N-neotetraose (LNnt) containing N-acetyllactosamine
KR20140001198A (ko) 2010-07-16 2014-01-06 글리콤 에이/에스 신규 시알로올리고당 유도체들의 합성
US20130344045A1 (en) 2010-12-29 2013-12-26 Nestec S.A. Nutritional composition comprising fiber and probiotics for reducing stress-related intestinal symptoms
BR112013016929A2 (pt) 2010-12-31 2019-09-24 Abbott Lab oligossacarídeos de leite humano para promover o crescimento de bactérias benéficas
AU2012215042B2 (en) 2011-02-10 2016-01-14 Société des Produits Nestlé S.A. Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
US20140057868A1 (en) 2011-02-21 2014-02-27 Glycom A/S Catalytic hydrogenolysis of a composition of a mixture of oligosaccharide precursors and uses thereof
CN103443113A (zh) 2011-03-18 2013-12-11 格力康公司 新型含岩藻糖的糖类衍生物的合成
BR112013029208A2 (pt) 2011-05-13 2017-02-14 Glycom As método para preparar um ou mais oligossarídeos de leite humano ou derivados ou precursores dos mesmos, uso de oligossacarídeos, e, composto
EP2712362A4 (en) 2011-05-13 2014-12-24 Glycom As MANUFACTURE OF LACTO-N-TETRAOSE
BR112013029203A2 (pt) 2011-05-13 2016-08-09 Glycom As método para a preparação de um ou mais oligossacarídeos de leite humano, e, uso de oligossacarídeos de leite humano
US10639319B2 (en) 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
US20140235850A1 (en) 2011-09-30 2014-08-21 Glycom A/S Synthesis of hmo core structures
WO2013091660A1 (en) 2011-12-23 2013-06-27 Glycom A/S A method for obtaining crystalline lacto-n-tetraose and lacto-n-neotetraose precursors and mixtures thereof
US20150065702A1 (en) 2012-03-20 2015-03-05 Glycom A/S Synthesis of the Trisaccharide 3-O-Fucosyllactose and Intermediates Thereof
MX2014012362A (es) 2012-04-13 2015-05-07 Trustees Boston College Composición prebiótica y métodos de uso.
EP2842560A4 (en) 2012-04-23 2015-12-02 Univ Kyoto COMPOSITION TO PROMOTE THE GROWTH OF BIFIDOBAKTERIA
EP2708145B1 (en) * 2012-09-14 2016-05-04 Abbott Laboratories Nutritional compositions for use in methods for modulating corticosterone levels in psychologically stressed individuals
DK2708147T3 (da) 2012-09-14 2020-05-18 Abbott Lab Fremgangsmåder til forøgelse af hjernefunktionalitet under anvendelse af 2-fucosyl-lactose
HK1215521A1 (zh) 2012-12-18 2016-09-02 Abbott Laboratories 包含神经保护膳食寡糖的营养组合物
MY187609A (en) 2012-12-18 2021-10-04 Abbott Lab Human milk oligosaccharides to ameliorate symptoms of stress
KR20150131147A (ko) 2013-03-12 2015-11-24 네스텍 소시에테아노님 우울증을 갖는 대상을 위해 치료 섭생법을 선별하기 위한 검정법 및 방법
HK1231398A1 (zh) 2014-04-08 2017-12-22 Abbott Laboratories 使用人乳寡糖增强对病原体的粘膜先天免疫反应和/或检测的方法
US20150305384A1 (en) 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
US11040050B2 (en) * 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US20160346303A1 (en) * 2014-10-29 2016-12-01 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome
US20160243139A1 (en) 2014-10-29 2016-08-25 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US11040049B2 (en) * 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US20160287637A1 (en) 2014-12-08 2016-10-06 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
US10780103B2 (en) * 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
US10857168B2 (en) * 2016-02-24 2020-12-08 Glycom A/S Synthetic composition for microbiota modulation
US11224605B2 (en) * 2016-05-19 2022-01-18 Glycom A/S Synthetic composition
EP3589139A4 (en) * 2017-03-01 2020-12-23 Glycom A/S SYNTHETIC COMPOSITION FOR MICROBIOTE MODULATION
US11602545B2 (en) * 2017-12-05 2023-03-14 Glycom A/S Human milk oligosaccharides for treating migraine

Also Published As

Publication number Publication date
US20180369260A1 (en) 2018-12-27
WO2017071715A1 (en) 2017-05-04
DK3368046T3 (da) 2022-10-31
US11684630B2 (en) 2023-06-27
EP3368046B1 (en) 2022-07-27
ES2927009T3 (es) 2022-10-31
EP3368046A4 (en) 2019-07-03
US20210077513A1 (en) 2021-03-18
EP3368046A1 (en) 2018-09-05
CN108348535B (zh) 2021-08-31
CN108348535A (zh) 2018-07-31
US10835545B2 (en) 2020-11-17

Similar Documents

Publication Publication Date Title
IL286669A (en) Compounds and methods for modulating tmprss6 expression
IL285229A (en) Compounds and methods for modulating RNA function
IL271659A (en) Compositions and methods for modulating expression of complement factor B
ZA201801600B (en) Compounds and methods for modulating angiotensinogen expression
DK3368046T3 (da) Synthetic composition and method for modulating brain function and behaviour
IL254780A0 (en) Electro-optical modulator
GB201512283D0 (en) Track behaviour events
IL247389A0 (en) Methods and preparations for personal pain management
HUE042875T2 (hu) Rendszerek és eljárások modulációs és kódolási séma választásra és konfigurálásra
PT3353303T (pt) Composições e métodos para modulação da expressão de ataxina 3
EP3193865A4 (en) Methods for treating brain metastasis
GB201504222D0 (en) Droplet assemblies and methods for producing droplet assemblies
GB201520255D0 (en) Composition and method
GB201611699D0 (en) Behaviour modification
IL254197A0 (en) Methods to modulate bone density
SG11201705265RA (en) Composition for forming underlayer and method for forming underlayer therewith
GB201601470D0 (en) Method and composition
GB201509420D0 (en) Composition and method
GB201513492D0 (en) Method and composition
GB201401612D0 (en) Synthetic method
PL3650431T3 (pl) Kompozycja zawierająca C<sub>8</sub>F<sub>17</sub>Br i sposób wytwarzania C<sub>8</sub>F<sub>17</sub>Br
ZA201803467B (en) Management method
GB201712304D0 (en) Synthetic methods
GB201621716D0 (en) Composition and method for bone regeneration
GB201601185D0 (en) Method and composition